PharmaTelevision - Argos Therapeutics: Technology Platforms, HIV immunotherapy and Partnering

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Argos Therapeutics: Technology Platforms, HIV immunotherapy and Partnering

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Paul Larsmon talks with John Bonfiglio, CEO at Argos Therapeutics.

Filmed at BIO-Europe 2009, they discuss:

• The company’s origins

• Argos’ platform technologies to combat infectious diseases and cancer

• the US$ 21M National Institutes of Health (NIH) contract to develop Argos’ Arcelis HIV immunotherapy platform

• The company’s search for a partner for developing CD83, a soluble recombinant protein proving to be an effective immunosuppressant in several mouse model systems

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The company's origins

Paul Larsmon:

Hello and welcome to BIO-Europe 2009 here in the Austrian capital of Vienna. With me is John Bonfiglio, the CEO of Argos Therapeutics. Welcome John.

John Bonfiglio:

Thank you Paul.

Paul Larsmon:

Tell me little bit about your company first of all?

John Bonfiglio:

Argos is a company that's located in Durham, North Carolina. It's been around since around 2001. We are involved in cell therapy in particularly we are doing autologous personalized cell therapy for the treatment of infectious disease and cancer. And the whole company was founded on the concept of being able to use this technology as a platform technology so that one particular technology can be used to treat many different types of disease, all components of the product come from the patient themselves that's the unique about the product.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

John Bonfiglio
CEO
Argos Therapeutics

John Bonfiglio joined Argos Therapeutics in 2007. Before joining Argos, Dr. Bonfiglio was President and CEO of Immune Response Corporation, where he led that company’s business development strategy and oversaw multiple clinical trials, manufacturing and the development of biologic immuno-stimulatory therapeutic agents. Prior to joining Immune Response, Dr. Bonfiglio served as Chief Operating Officer and Executive Vice President of Cypress Bioscience, where his responsibilities included business development, marketing, research and development, clinical development, strategic direction, and budgeting. He has also served as President and CEO of Peregrine Pharmaceuticals, as Director of the Strategic Business Unit at Baxter Healthcare Corporation, and as Director of Business Planning at Allergan. Dr. Bonfiglio holds an M.B.A. from Pepperdine University and received his Ph.D. and Masters in Organic Chemistry from University of California – San Diego. He received a Bachelors degree in Chemistry from the State University of New York – Stony Brook.

Argos Therapeutics

Argos Therapeutics is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells – the master switch that turns the immune system on or off.